Shares of Hikma Pharmaceuticals PLC HIK inched down 0.93% to £18.09 Wednesday, on what proved to be an all-around favorable trading session for the stock market, with the FTSE 100 Index UKX rising ...

Shares of Hikma Pharmaceuticals PLC HIK rallied 1.64% to £18.01 Thursday, on what proved to be an all-around poor trading ...

Analyst Christian Glennie from Stifel Nicolaus reiterated a Buy rating on Hikma Pharmaceuticals (HIK – Research Report) and keeping the ...

Hikma Pharmaceuticals (GB:HIK) has released an update. Hikma Pharmaceuticals has decided to reappoint PricewaterhouseCoopers LLP as its external auditor starting in 2026, following a competitive ...

But if you try your hand... Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep.

Hikma Pharmaceuticals reiterated its full-year outlook on Thursday on the back of strong trading across the business.

The company also reiterated guidance for its Branded business of revenue in the high-single digits, or 6% to 8% higher year-on-year, with a core operating margin around 25%. Its Generics business is ...

Hikma Pharmaceuticals PLC (LON:HIK – Get Free Report)’s stock price passed above its two hundred day moving average during trading on Tuesday .The stock has a two hundred day moving average of ...

(Alliance News) - Hikma Pharmaceuticals PLC on Thursday said it is on track to deliver "another strong performance" following trading to date, and reiterates its full-year revenue expectations.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...